Ask AI

Combating Myeloma: Improving Access and Outcomes With CAR T-Cell and Bispecific Antibody Therapies in Veterans With Relapsed/Refractory Multiple Myeloma

Learn more about patient and disease characteristics guiding the selection of CAR T-cell therapy and bispecific antibodies in the individualization of treatment of veterans with relapsed/refractory multiple myeloma and optimal strategies to integrate and sequence immunotherapies for these patients through an on-demand webcast, expert-authored commentary, and downloadable slides.

Share

Program Content

Activities

CAR T Cell and Bispecific Antibodies in Multiple Myeloma
Combating Myeloma: Improving Access and Outcomes With CAR T-Cell and Bispecific Antibody Therapies in Veterans With Relapsed/Refractory Multiple Myeloma
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 25, 2025

Provided by

ProCE Banner

Clinical Care Options, LLC.

Supporters

Supported by educational grants from Bristol Myers Squibb and Johnson & Johnson.

Bristol Myers Squibb

Johnson & Johnson